ABL Bio Reveals Research Results at Global Dementia Conference... IND Application Planned for Next Year

[Asia Economy Reporter Hyungsoo Park] ABL Bio will present its bispecific antibody treatment for Parkinson's disease, ABL301, at a world-renowned dementia and Parkinson's treatment conference.

On the 1st, ABL Bio announced that it has been officially invited by the conference to present a poster and give an oral presentation on the research results and efficacy of ABL301.

AAT-AD/PD™ is a global professional conference on dementia and Parkinson's disease treatment held in Vienna.

ABL301 is a bispecific antibody under development as a Parkinson's disease treatment that combines a BBB (Blood Brain Barrier) platform capable of crossing the blood-brain barrier with a target that inhibits the aggregation and propagation of alpha-synuclein, the cause of Parkinson's disease, within the brain.

Existing treatments for degenerative brain diseases have limitations in that they cannot be properly delivered into the brain due to the blood-brain barrier (BBB). In contrast, ABL301 uses the Grabody™-B platform, a kind of 'transport vehicle,' to significantly increase BBB permeability compared to conventional monoclonal antibody treatments, demonstrating sufficient efficacy in animal experiments. The Grabody™-B platform has attracted considerable interest from numerous overseas pharmaceutical companies.

ABL Bio confirmed that after administering ABL301 in an alpha-synuclein overexpressing Parkinson's disease animal model, it improved representative phenomena of Parkinson's disease such as brain protein aggregation (Lewy Body) and neuronal loss (loss of dopaminergic neurons in the substantia nigra). In motor function impairment tests, the ABL301-treated group showed remarkable improvement in motor function not only in Parkinson's disease but also in multiple system atrophy, a distinct neurological disorder.

The animal model experiments of ABL301 presented at the conference successfully reproduced the animal model devised by the Virginia Lee Laboratory, a pioneer in neuroscience. This has attracted significant attention among pharmaceutical industry stakeholders and overseas pharmaceutical companies.

Recently, safety was verified through preliminary toxicity animal experiments involving repeated administration. Through ongoing preclinical in vivo efficacy experiments and additional safety verification in animal models, ABL Bio plans to apply for clinical trial approval (IND) in the first half of next year.

This content was produced with the assistance of AI translation services.